Emerging Data and Perspectives in the Management of ATTR Cardiac Amyloidosis

Transthyretin amyloid cardiomyopathy (or ATTR-CM) is a serious, underrecognized, and underdiagnosed cause of heart failure. Through a patient case study and expert perspectives, this program will explore the patient journey for ATTR-CM and data supporting an oral treatment option for patients with this progressive disease.

Sponsored by Pfizer